Clinical Development of ADCs for Solid Tumors: 40 Years of Progress
Clinical Development of ADCs for Solid Tumors The currently approved ADCs for solid tumors are listed in the table below: ADCs Target Indications T-DM1 HER2 HER2-positive metastatic breast cancer SG (sacituzumab govitecan) Trop2 Triple-negative breast cancer (TNBC) Metastatic urothelial carcinoma (mUC) sacituzumab tirumotecan Trop2 TNBC, NSCLC Gastric cancer/gastroesophageal junction cancer, mUC enfortumab vedotin Nectin-4 Locally … Read more